Medicare Coverage for Anti-Amyloid Antibodies

Medicare Coverage for Anti-Amyloid Antibodies

CMS provides Medicare coverage for traditionally FDA-approved monoclonal antibodies directed against amyloid when national coverage criteria are met. CMS currently requires qualifying data submission through an approved study/registry pathway for covered treatment.

For Medicare beneficiaries, eligibility and out-of-pocket costs depend on coverage, treatment setting, supplemental insurance, and other factors. Coverage should be verified before treatment.